学者信息

罗文新 (WenXin Luo)

公共卫生学院

ResearcherID:G-4640-2010

合作者

已发表成果:

WOK 论文 52 篇;中文核心 34 篇;其它论文 11 篇;专利发明 16 个;

  • Structural basis for the synergistic neutralization of coxsackievirus B1 by a triple-antibody cocktail

    CELL HOST & MICROBE,1931-3128,2022-09-14.
    Zheng, Qingbing; Zhu, Rui; Yin, Zhichao; Xu, Longfa; Sun, Hui; Yu, Hai; Wu, Yuanyuan; Jiang, Yichao...
    WOS:000889279600001   10.1016/j.chom.2022.08.001
    收录情况:SCIE
  • Research progress and applications of nanobody in human infectious diseases

    FRONTIERS IN PHARMACOLOGY,,2022-08-12.
    Mei, Yaxian; Chen, Yuanzhi; Sivaccumar, Jwala P. P.; An, Zhiqiang; Xia, Ningshao; Luo, Wenxin
    WOS:000844886000001   10.3389/fphar.2022.963978
    收录情况:SCIE
  • Development of functional antibodies against influenza B virus by activation-induced cytidine deaminase in hybridoma cells

    VIROLOGICA SINICA,1674-0769,2022-08.
    Chen, Yuanzhi; Shen, Chenguang; Chen, Jing; Chen, Junyu; Chen, Fentian; Zhang, Limin; Liu, Xue; Che...
    WOS:000848606000002   10.1016/j.virs.2022.03.0091995-820X
    收录情况:SCIE
  • Development of functional antibodies against influenza B virus by activation-induced cytidine deaminase in hybridoma cells

    VIROLOGICA SINICA,1674-0769,2022-08.
    Chen, Yuanzhi; Shen, Chenguang; Chen, Jing; Chen, Junyu; Chen, Fentian; Zhang, Limin; Liu, Xue; Che...
    WOS:000861188100001   10.1016/j.virs.2022.03.009
    收录情况:SCIE
  • Recent progress in antibody-based therapeutics for triple-negative breast cancer

    EXPERT OPINION ON DRUG DELIVERY,1742-5247,2022-07-03.
    Ning, Wen-Jing; Liu, Xue; Zeng, Hong-Ye; An, Zhi-Qiang; Luo, Wen-Xin; Xia, Ning-Shao
    WOS:000824410200004   10.1080/17425247.2022.2093853
    收录情况:SCIE
  • Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade

    JOURNAL FOR IMMUNOTHERAPY OF CANCER,,2022-06.
    Ju, Fei; Luo, Yong; Lin, Chaolong; Jia, Xian; Xu, Zilong; Tian, Rui; Lin, Yanhua; Zhao, Min; Chang,...
    WOS:000810551500006   10.1136/jitc-2022-004762
    收录情况:SCIE
  • HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities

    CLINICAL AND TRANSLATIONAL MEDICINE,2001-1326,2022-04.
    Chu, Wendi; Xu, Hui; Wang, Yanfei; Xie, Yongle; Chen, Yi-Li; Tan, Xiaorong; Huang, Chenghao; Wang, ...
    WOS:000778130600001   10.1002/ctm2.791
    收录情况:SCIE
  • A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy

    NATURE NANOTECHNOLOGY,1748-3387,2022-04.
    Liu, Chao; Liu, Xue; Xiang, Xinchu; Pang, Xin; Chen, Siyuan; Zhang, Yunming; Ren, En; Zhang, Lili; ...
    WOS:000780825800002   EI:20221611971933   10.1038/s41565-022-01098-0
    收录情况:SCIE、EI
  • A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy

    ANTIVIRAL RESEARCH,0166-3542,2022-03.
    Wang, Yue; Mei, Yaxian; Ao, Zhenghong; Chen, Yuanzhi; Jiang, Yichao; Chen, Xiaoqing; Qi, Ruoyao; Fu...
    WOS:000795699400007   10.1016/j.antiviral.2022.105265
    收录情况:SCIE
  • CAR-T联合疗法治疗实体瘤的研究进展

    中国生物工程杂志,1671-8135,2022-12-25.
    林宏伟;刘珺懿;罗文新
    CSCD核心
  • ADC药物的抗体组成及其作用靶点研究进展

    中国生物工程杂志,1671-8135,2022-05-25.
    曾弘烨;宁文静;罗文新
    CSCD核心
  • 白细胞介素12在实体瘤治疗中的研究进展

    肿瘤研究与临床,1006-9801,2022-08-28.
    武可欣;陈奋天;罗文新